Medical publishing does not stand still and, to paraphrase the Greek philosopher Heraclitus of Ephesus, 'The only thing that is constant is change'. This is my first issue as BJD Editor, having taken on leadership of the journal from Alex Anstey on 1 July. I am delighted that Eleni Linos, Stanford University, California, and Neil Rajan, Newcastle University, U.K., have joined the BJD senior editorial team as Deputy Editors. While Editor of BJD from 2013 to 2019, Alex Anstey undertook a prodigious change process to ensure that the BJD remains a top dermatology journal. Importantly, Alex started from first principles, asking the question 'What does the BJD now stand for?'. 1 A consensus position statement emerged, in which the BJD strives to publish the highest-quality research encompassing clinical trials, epidemiology, outcomes and qualitative research, and translational research that describes basic science of potential clinical relevance. Journal enhancements have flowed from the mission statement. The next step was to assemble a senior editorial team of stellar clinical academics for each journal section (take a look at the journal team on our website). 2 Our editorial team of section and associate editors increased in number from less than 20 to nearly 80 in a 5-year period (Fig. 1), with close to a 1 : 1 gender balance and a wide geographical spread across the continents. 3 Once the team was in place, we moved onto considering how to add value to original articles for our readers and authors. Under Alex's leadership, most BJD original articles are accompanied by a plain language summary in English and